283. 後天性赤芽球癆 [臨床試験数:17,薬物数:36(DrugBank:19),標的遺伝子数:16,標的パスウェイ数:91

Searched query = "Acquired pure red cell aplasia", "Pure red cell aplasia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04470804August 1, 20209/7/2020Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCASirolimus Treatment for Newly Diagnosed Primary Acquired Pure Red Cell Aplasia: a Single Center Prospective StudyPure Red Cell Aplasia, AcquiredDrug: Sirolimus;Drug: Cyclosporine ABing HanNULLNot yet recruiting18 Years70 YearsAll40Phase 4China
2NCT03364764January 201821/11/2017Sirolimus Treatment for Refractory PRCASirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective StudyPure Red Cell AplasiaDrug: SirolimusBing HanNULLRecruiting18 Years80 YearsAll30Phase 4China
3NCT03214354July 5, 20175/7/2017Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling DonorA Phase II Pilot Study of Nonmyeloablative Conditioning Hematopoietic Stem Cell Transplantation in Children With Sickle Cell Disease Who Have a Matched Related Major ABO-Incompatible Donor (Sickle-MAID)Sickle Cell Disease;Stem Cell Transplant Complications;Red Blood Cell Disorder;Pure Red Cell AplasiaDrug: Alemtuzumab;Radiation: Total Body Irradiation;Drug: SirolimusUniversity of CalgaryNULLRecruiting1 Year19 YearsAll12Phase 2Canada